GD2-направленная иммунотерапия нейробластомы группы высокого риска с использованием химерных антител ch14.18
Voprosy gematologii/onkologii i immunopatologii v pediatrii(2020)
Abstract
Neuroblastoma is the most common extracranial solid tumor in children 0–14 years old. Current risk-adapted treatment programs are based on stratification of patient into three risk groups. 40–50% of patients are stratified into the high-risk group. The prognosis in high-risk patients remains poor (the probability of long-term survival is less than 50%), despite the use of aggressive multimodal therapy, including high-dose chemotherapy and autologous hematopoietic stem cell transplantation. In most cases tumor cells in neuroblastoma express disialoganglioside GD2, which is a possible target for immunotherapy. Over the past 30 years, GD2-directed chimeric monoclonal antibodies ch14.18 have been introduced into clinical practice. A number of clinical studies have shown an improvement in the prognosis in patients with high-risk neuroblastoma, when using monoclonal antibodies ch14.18, primarily due to the eradication of the minimal residual population of tumor cells resistant to standard chemotherapy. This literature review summarizes the international experience in the use of monoclonal antibodies ch14.18 from early phases of clinical trials to large randomized trials, which allowed immunotherapy to be considered as an important component of multimodal therapy for high-risk neuroblastoma. Future prospects for the use and place of immunotherapy in first-line therapy of high-risk neuroblastoma and in relapsed setting are considered.
MoreTranslated text
Key words
Neuroblastoma
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined